Moomoo AI 已提取核心信息
On December 29, 2023, The Vanguard Group filed an amended Schedule 13G/A with the SEC, indicating a change in their holdings of Altimmune Inc's common stock. The filing revealed that The Vanguard Group now beneficially owns 3,571,972 shares of Altimmune, which represents 6.65% of the company's class of common stock. This position is a mix of shared and sole voting and dispositive power, with the majority being sole dispositive power at 3,529,736 shares. The Vanguard Group, headquartered in Pennsylvania, is an investment adviser and reports that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of Altimmune Inc. The updated ownership information was officially filed with the SEC on February 13, 2024.
On December 29, 2023, The Vanguard Group filed an amended Schedule 13G/A with the SEC, indicating a change in their holdings of Altimmune Inc's common stock. The filing revealed that The Vanguard Group now beneficially owns 3,571,972 shares of Altimmune, which represents 6.65% of the company's class of common stock. This position is a mix of shared and sole voting and dispositive power, with the majority being sole dispositive power at 3,529,736 shares. The Vanguard Group, headquartered in Pennsylvania, is an investment adviser and reports that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of Altimmune Inc. The updated ownership information was officially filed with the SEC on February 13, 2024.
2023年12月29日，Vanguard集团向美国证券交易委员会提交了经修订的附表13G/A，表明其持有的Altimmune Inc普通股发生了变化。文件显示，Vanguard集团现在实益拥有Altimmune的3571,972股股份，占该公司普通股类别的6.65％。该立场混合了共享和唯一投票权和处置权，其中多数是唯一的处置权，为3,529,736股。总部位于宾夕法尼亚州的Vanguard Group是一家投资顾问，该公司报告称，这些证券是在正常业务过程中收购的，其目的不是改变或影响Altimmune Inc.的控制权。更新的所有权信息已于2024年2月13日正式向美国证券交易委员会提交。
2023年12月29日，Vanguard集团向美国证券交易委员会提交了经修订的附表13G/A，表明其持有的Altimmune Inc普通股发生了变化。文件显示，Vanguard集团现在实益拥有Altimmune的3571,972股股份，占该公司普通股类别的6.65％。该立场混合了共享和唯一投票权和处置权，其中多数是唯一的处置权，为3,529,736股。总部位于宾夕法尼亚州的Vanguard Group是一家投资顾问，该公司报告称，这些证券是在正常业务过程中收购的，其目的不是改变或影响Altimmune Inc.的控制权。更新的所有权信息已于2024年2月13日正式向美国证券交易委员会提交。
有用
没用